Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679886 | 0.86 | KDM4E (0.38) | ALDH1A1MAPTKDM4ETSHRRAB9A | |
| SCHEMBL6679462 | 0.85 | ALDH1A1 (0.36) | TP53ALDH1A1KDM4ETSHRP2RX7 | |
| SCHEMBL6683536 | 0.84 | TRPA1 (0.45) | TP53ALDH1A1MAPTTRPA1 | |
| SCHEMBL6681574 | 0.84 | ALDH1A1 (0.36) | TP53ALDH1A1MAPTKDM4EPKM | |
| SCHEMBL6682928 | 0.82 | TP53 (0.36) | TP53ALDH1A1MAPTKDM4EPKM | |
| SCHEMBL6718409 | 0.77 | THRB (0.43) | TP53ALDH1A1MAPTKDM4ETSHR | |
| SCHEMBL6685075 | 0.72 | TRPA1 (0.43) | TP53ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL6679418 | 0.72 | PTGDR2 (0.36) | ALDH1A1KDM4ETSHRP2RX7RAB9A | |
| SCHEMBL6682041 | 0.71 | MAPK14 (0.39) | ALDH1A1MAPTKDM4ETSHRRAB9A | |
| SCHEMBL6684363 | 0.71 | TRPA1 (0.46) | ALDH1A1MAPTKDM4ERAB9ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014354-A1 | 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | TP53 2960/4885ALDH1A1 430/4885MAPT 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.